drugset / Trial / NCT00189514

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

NCT00189514

Phase 2 Completed 210 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

Timeline

Start
2005-09
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramlintide Peptide 120 ug Subcutaneous
Subject Pramlintide Peptide 240 ug Subcutaneous
Subject Pramlintide Peptide 360 ug Subcutaneous

Indications